American Society of Nephrology Annual Meeting
American Society of Nephrology Annual Meeting
Source/Disclosures
Source:

Provenzano R, et al. Paper SA-OR39. Presented at: ASN Kidney Week. Oct. 22-25, 2020 (virtual meeting).

Disclosures: Provenzano reports he is employed by DaVita Inc. and is a consultant for and has received honoraria from Fibrogen Inc. and AstraZeneca plc. The study received commercial support from Fibrogen Inc.
October 26, 2020
1 min read
Save

Roxadustat cuts risk of congestive heart failure in patients with ESKD

Source/Disclosures
Source:

Provenzano R, et al. Paper SA-OR39. Presented at: ASN Kidney Week. Oct. 22-25, 2020 (virtual meeting).

Disclosures: Provenzano reports he is employed by DaVita Inc. and is a consultant for and has received honoraria from Fibrogen Inc. and AstraZeneca plc. The study received commercial support from Fibrogen Inc.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients who underwent dialysis and were prescribed roxadustat had a 27% reduction in risk for hospitalization for congestive heart failure compared with patients who took epoetin alfa, according to a study.

“[Congestive heart failure] CHF is associated with a poorer prognosis in [chronic kidney disease] CKD patients, with a prevalence that increases with CKD severity; approximately 20% in mild CKD (> 65 years) to 40% in patients on hemodialysis,” Robert Provenzano, MD, and colleagues wrote in an abstract presented at ASN Kidney Week.

Researchers reviewed data from phase 3 studies that compared roxadustat with placebo in patients with stage 3 to 5 CKD and with epoetin alfa in prevalent patients with end-stage kidney disease on dialysis. Data from a subgroup of patients on dialysis for 4 months or less were also reviewed.

Robert Provenzano

In the pooled studies, 1,940 patients on dialysis received roxadustat and 1,940 patients received epoetin alfa. The baseline history of CHF in both arms was comparable between roxadustat (25.7%) and epoetin alfa (25.3%).

Results showed patients on dialysis who received roxadustat had a 27% reduction in risk for CHF hospitalization compared with patients who received epoetin alfa. Researchers also reported a trend toward reduction of risk compared with placebo in patients with CKD who were not on dialysis and compared with epoetin alfa in patients starting dialysis. Provenzano said the trend was not significant.